| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b603ecd95b3b1497ae9f30752a676c0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e03421731262628441ad5f79dc2bd04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_647c0c1bcef3976dc182ceb8595d7909
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 |
| filingDate |
2018-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fe47b9bf04d97db2d2ac2a70246d0fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d9ae2b7a5dccfeee995d563783f978f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a281b6484e8993ea9cfbe9d5dc39758 |
| publicationDate |
2021-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021205276-A1 |
| titleOfInvention |
Combination treatment of pancreatic cancer |
| abstract |
PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant mechanisms leading to a common downstream signalling. The inventors questioned this concept, by mapping differential isoform-specific downstream signalling in response to their constant selective inhibition in pancreatic cancer, a disease currently without therapy. They identified common and specific signals activated by each PI3K isoform. These data make the rational for the development of highly selective PI3K isoform drugs used in combination, instead of compounds inhibiting all PI3Ks. In particular, the inventors showed that combined p110a and 110γ inhibition is the most efficient strategy for pancreatic cancer patients. |
| priorityDate |
2017-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |